Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04925687
Status:
COMPLETED
Last Update Posted:
2024-05-08
First Post:
2021-06-02
Brief Title:
Phase 1 Study of Intravitreal Autologous CD34 Stem Cell Therapy for Retinitis Pigmentosa
Sponsor:
University of California Davis
Organization:
University of California Davis
Study Overview
Official Title:
Phase 1 Study of the Feasibility and Safety of Intravitreal Autologous Bone Marrow CD34 Stem Cell Therapy for Eyes With Vision Loss From Retinitis Pigmentosa
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BMSCRP1
Brief Summary:
In this Phase 1 open-labeled prospective study one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34 stem cells harvested from bone marrow Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None